The report by the Institute of Medicine and postmarketing surveillance

被引：0
|
作者：
Klein, DF [1 ]
机构：
[1] New York State Psychiat Inst, Unit 22, New York, NY 10032 USA
来源：
ARCHIVES OF GENERAL PSYCHIATRY | 1999年 / 56卷 / 04期
关键词：
D O I：
10.1001/archpsyc.56.4.353
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：353 / 354
页数：2
相关论文
共 50 条
  • [1] Role of Postmarketing Surveillance in Contemporary Medicine
    Woodcock, Janet
    Behrman, Rachel E.
    Dal Pan, Gerald J.
    ANNUAL REVIEW OF MEDICINE, VOL 62, 2011, 2011, 62 : 1 - 10
  • [2] Institute of Medicine: FDA should tighten postmarketing activities
    Reactions Weekly, 2012, 1401 (1) : 4 - 4
  • [3] US FDA posts report on postmarketing surveillance
    Reactions Weekly, 2019, 1766 (1) : 3 - 3
  • [4] OTA REPORT REVIVES QUESTION OF POSTMARKETING SURVEILLANCE
    不详
    DRUG & COSMETIC INDUSTRY, 1983, 132 (03): : 30 - &
  • [5] CYCLOBENZAPRINE (FLEXERILTM) - REPORT OF A POSTMARKETING SURVEILLANCE PROGRAM
    NIBBELINK, DW
    STRICKLAND, SC
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1980, 28 (06): : 894 - 903
  • [6] POSTMARKETING SURVEILLANCE
    VOSS, S
    HARRIS, F
    BRITISH MEDICAL JOURNAL, 1994, 309 (6948): : 194 - 194
  • [7] POSTMARKETING SURVEILLANCE
    DENES, G
    MUNCHENER MEDIZINISCHE WOCHENSCHRIFT, 1990, 132 (23): : 373 - 375
  • [8] Institute of Medicine - Report
    Meakins, JI
    CANADIAN JOURNAL OF SURGERY, 2000, 43 (02) : 84 - 85
  • [9] Postmarketing surveillance is needed
    Srinivas, VR
    BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7456): : 51 - 51
  • [10] POSTMARKETING SURVEILLANCE OF THE SAFETY OF CIMETIDINE - 10 YEAR MORTALITY REPORT
    COLINJONES, DG
    LANGMAN, MJS
    LAWSON, DH
    LOGAN, RFA
    PATERSON, KR
    VESSEY, MP
    GUT, 1992, 33 (09) : 1280 - 1284
12345